Krensavage Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16M | Sell |
|
|||||
|
2025
Q1 | $11.7M | Sell |
|
|||||
|
2024
Q4 | $12.2M | Buy |
|
|||||
|
2024
Q3 | $15.5M | Buy |
|
|||||
|
2024
Q2 | $16.2M | Buy |
|
|||||
|
2024
Q1 | $19.6M | Buy |
|
|||||
|
2023
Q4 | $6.99M | Buy |
|
|||||
|
2023
Q3 | $8.21M | Buy |
|
|||||
|
2023
Q2 | $14.7M | Buy |
|
|||||
|
2023
Q1 | $24.4M | Buy |
|
|||||
|
2022
Q4 | $27.7M | Buy |
|
|||||
|
2022
Q3 | $30.6M | Sell |
|
|||||
|
2022
Q2 | $29.5M | Buy |
|
|||||
|
2022
Q1 | $39.1M | Sell |
|
|||||
|
2021
Q4 | $42.2M | Sell |
|
|||||
|
2021
Q3 | $53.2M | Sell |
|
|||||
|
2021
Q2 | $41.4M | Buy |
|
|||||
|
2021
Q1 | $42.6M | Buy |
|
|||||
|
2020
Q4 | $36.2M | Buy |
|
|||||
|
2020
Q3 | $37.8M | Buy |
|
|||||
|
2020
Q2 | $38.3M | Buy |
|
|||||
|
2020
Q1 | $36M | Buy |
|
|||||
|
2019
Q4 | $30.2M | Sell |
|
|||||
|
2019
Q3 | $30M | Buy |
|
|||||
|
2019
Q2 | $40.5M | Buy |
|
|||||
|
2019
Q1 | $45.5M | Sell |
|
|||||
|
2018
Q4 | $37.9M | Buy |
|
|||||
|
2018
Q3 | $43.7M | Sell |
|
|||||
|
2018
Q2 | $60.2M | Sell |
|
|||||
|
2018
Q1 | $59.9M | Sell |
|
|||||
|
2017
Q4 | $50.9M | Sell |
|
|||||
|
2017
Q3 | $47.4M | Sell |
|
|||||
|
2017
Q2 | $39.8M | Buy |
|
|||||
|
2017
Q1 | $33.8M | Buy |
|
|||||
|
2016
Q4 | $35.4M | Buy |
|
|||||
|
2016
Q3 | $26.6M | Buy |
|
|||||
|
2016
Q2 | $20M | Buy |
|
|||||
|
2016
Q1 | $25.9M | Buy |
|
|||||
|
2015
Q4 | $29M | Buy |
|
|||||
|
2015
Q3 | $26.4M | Buy |
|
|||||
|
2015
Q2 | $31.8M | Buy |
|
|||||
|
2015
Q1 | $13M | Buy |
|